About Rallybio Corporation
https://www.rallybio.comRallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT).
CEO
Stephen Uden M.B,
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 1 of 11
Ratings Snapshot
Rating : B
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
VIKING GLOBAL INVESTORS LP
Shares:4.19M
Value:$2.87M
JOHNSON & JOHNSON
Shares:3.64M
Value:$2.49M
5AM VENTURE MANAGEMENT, LLC
Shares:3.63M
Value:$2.49M
Summary
Showing Top 3 of 52
About Rallybio Corporation
https://www.rallybio.comRallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT).
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $212K | $7.14M ▼ | $16.02M ▲ | 7.55K% ▲ | $0.36 ▲ | $16.05M ▲ |
| Q2-2025 | $212K | $10.27M ▲ | $-9.7M ▼ | -4.58K% ▼ | $-0.22 ▼ | $-10.03M ▼ |
| Q1-2025 | $212K ▲ | $9.88M ▼ | $-9.44M ▲ | -4.45K% ▲ | $-0.21 ▲ | $-9.64M ▲ |
| Q4-2024 | $38K ▼ | $11.62M ▼ | $-11.04M ▲ | -29.06K% ▼ | $-0.25 ▲ | $-11.58M ▲ |
| Q3-2024 | $299K | $12.37M | $-11.47M | -3.83K% | $-0.26 | $-12.03M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $59.32M ▲ | $67.66M ▲ | $4.63M ▼ | $63.03M ▲ |
| Q2-2025 | $45.75M ▼ | $51M ▼ | $5.04M ▲ | $45.96M ▼ |
| Q1-2025 | $54.49M ▼ | $57.98M ▼ | $3.91M ▼ | $54.07M ▼ |
| Q4-2024 | $65.51M ▼ | $68.11M ▼ | $6.45M ▼ | $61.65M ▼ |
| Q3-2024 | $75.14M | $79.01M | $8.19M | $70.82M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $16.02M ▲ | $-6.55M ▲ | $29.23M ▲ | $0 ▼ | $22.68M ▲ | $-6.55M ▲ |
| Q2-2025 | $-9.7M ▼ | $-8.38M ▲ | $3.04M ▼ | $10K ▲ | $-5.33M ▼ | $-8.38M ▲ |
| Q1-2025 | $-9.44M ▲ | $-10.21M ▼ | $11.08M ▲ | $0 ▼ | $876K ▲ | $-10.21M ▼ |
| Q4-2024 | $-11.04M ▲ | $-9.86M ▲ | $-1.57M ▼ | $18K ▲ | $-11.42M ▼ | $-9.86M ▲ |
| Q3-2024 | $-11.47M | $-13.54M | $22.2M | $-11K | $8.65M | $-13.54M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Collaboration And License Revenue | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Stephen Uden M.B,
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 1 of 11
Ratings Snapshot
Rating : B
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
VIKING GLOBAL INVESTORS LP
Shares:4.19M
Value:$2.87M
JOHNSON & JOHNSON
Shares:3.64M
Value:$2.49M
5AM VENTURE MANAGEMENT, LLC
Shares:3.63M
Value:$2.49M
Summary
Showing Top 3 of 52